Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
trenddetector
trenddetector Apr. 3 at 4:13 PM
$RHHBY Built a free tool to help navigate cancer treatment options and clinical trials — would really appreciate feedback https://nimble-frangollo-81ff5e.netlify.app/
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 3 at 2:49 PM
$OMER again show me another pre clinical to fda approved never had a reverse split. Just got 240 million upfront cash follow up up to 2.1 billion. Ceo is a legend Double surgeon orthopedic stanford and duke pages of medical patent. Dude is overqualified for life. Alien 👽 👾 https://patents.justia.com/inventor/thomas-dudler $RGC $PFE $RHHBY
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 2 at 4:53 PM
$OMER is domestic doesn't apply if you don't have a drug to sell. $NVO $HIMS $RHHBY Commercial distribution and sales of YARTEMLEA began in January 2026. Both adult and pediatric patients with TA-TMA are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5- and C3-inhibitor regimens, in both hospital and outpatient settings. We are commercializing YARTEMLEA in the U.S. market and have deployed our field force of account managers and directors, market development managers, access leads, and medical science liaisons to engage directly with transplant centers across the United States.
0 · Reply
scotttrader213
scotttrader213 Apr. 1 at 2:53 PM
$RHHBY nice comeback as it moves higher once again
0 · Reply
Quantumup
Quantumup Apr. 1 at 12:57 PM
BofA⬆️ $SRRK's PT to $58 from $51 and reiterated at a Buy rating. $RHHBY LLY NVO PTCT IONS - $BIIB BofA said in its note—SRRK announced resubmission of its BLA for apitegromab (api) in spinal muscular atrophy following a positive Type C meeting on Mar 3. With FDA alignment, two fill-finish partners are included in the filing with the company expecting a late-Sept PDUFA goal date for the Class II re-filing. We view applying with two mfg options for US approval to be highly encouraging as it de-risks the sole approvability issue cited in the 2025 CRL for api. Based on this update, we update our US launch timeline to 4Q26 from mid-27 and reiterate our Buy rating with higher $58 PO (see model changes inside).
0 · Reply
patatechaude
patatechaude Apr. 1 at 12:09 PM
$NVS $OLMA $RHHBY $XBI Will we get a buyout PR soon?
0 · Reply
green_going_up
green_going_up Apr. 1 at 3:50 AM
$CLGN Aesthetic Wellness is one of the fastest growing markets; this firm has a development deal with $ABBV yet can't get any interest; reminds me of $LCTX which has a development deal with $RHHBY for GA; these firms get tiny milestone payments and just sit there waiting, hoping, and praying for these big firms to fully commit. They can take YEARS. And, you wonder if firm's like Abbvie and Roche don't just play the long game on purpose, eventually being able to pick up these micro-cap firm assets on the cheap once either these firms file for bankruptcy or dilute themselves so much because the shorts / naked shorts just pound them relentless until they are forced to de-list. Firms like these micro-cap ones MUST have really strong CFO's to raise way more than what's needed - Years Worth of Cash - in the period right after the initial partnership announcement spike. Otherwise, surviving the waiting game is a serious challenge.
2 · Reply
patatechaude
patatechaude Mar. 31 at 7:19 PM
Come on $NVS, make your offer… get $OLMA and beat $RHHBY to it. $3B should do. $XBI
0 · Reply
Lowkeyoptions
Lowkeyoptions Mar. 30 at 8:42 PM
$BFRG Based on 2024–2025 revenue data, the top pharmaceutical companies are dominated by Pfizer, Merck & Co., Johnson & Johnson, AbbVie, and Roche. These companies lead in manufacturing vaccines, oncology drugs, and innovative therapies, with several, particularly Pfizer, rebounding from lower COVID-19 product demand. Top 5 Pharmaceutical Companies (by 2024/2025 Revenue): $PFE Often leads by revenue due to COVID-19 vaccines and vaccines like Prevnar, though facing pressure to diversify. $MERCK (USA): Known for cancer immunotherapy Keytruda, which has driven significant growth, placing them high in the rankings. $JNJ Johnson & Johnson (USA): A diversified healthcare leader with strong positions in pharmaceuticals and medical $ABBV (USA): Known for immunology treatments like Humira, maintaining a top spot despite patent challenges. $RHHBY Roche (Switzerland): A leader in oncology and diagnostics, often ranking top five due to its specialized, high-cost therapies.
0 · Reply
scotttrader213
scotttrader213 Mar. 30 at 7:54 PM
$RHHBY holding steady
0 · Reply
Latest News on RHHBY
No data available.
trenddetector
trenddetector Apr. 3 at 4:13 PM
$RHHBY Built a free tool to help navigate cancer treatment options and clinical trials — would really appreciate feedback https://nimble-frangollo-81ff5e.netlify.app/
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 3 at 2:49 PM
$OMER again show me another pre clinical to fda approved never had a reverse split. Just got 240 million upfront cash follow up up to 2.1 billion. Ceo is a legend Double surgeon orthopedic stanford and duke pages of medical patent. Dude is overqualified for life. Alien 👽 👾 https://patents.justia.com/inventor/thomas-dudler $RGC $PFE $RHHBY
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 2 at 4:53 PM
$OMER is domestic doesn't apply if you don't have a drug to sell. $NVO $HIMS $RHHBY Commercial distribution and sales of YARTEMLEA began in January 2026. Both adult and pediatric patients with TA-TMA are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5- and C3-inhibitor regimens, in both hospital and outpatient settings. We are commercializing YARTEMLEA in the U.S. market and have deployed our field force of account managers and directors, market development managers, access leads, and medical science liaisons to engage directly with transplant centers across the United States.
0 · Reply
scotttrader213
scotttrader213 Apr. 1 at 2:53 PM
$RHHBY nice comeback as it moves higher once again
0 · Reply
Quantumup
Quantumup Apr. 1 at 12:57 PM
BofA⬆️ $SRRK's PT to $58 from $51 and reiterated at a Buy rating. $RHHBY LLY NVO PTCT IONS - $BIIB BofA said in its note—SRRK announced resubmission of its BLA for apitegromab (api) in spinal muscular atrophy following a positive Type C meeting on Mar 3. With FDA alignment, two fill-finish partners are included in the filing with the company expecting a late-Sept PDUFA goal date for the Class II re-filing. We view applying with two mfg options for US approval to be highly encouraging as it de-risks the sole approvability issue cited in the 2025 CRL for api. Based on this update, we update our US launch timeline to 4Q26 from mid-27 and reiterate our Buy rating with higher $58 PO (see model changes inside).
0 · Reply
patatechaude
patatechaude Apr. 1 at 12:09 PM
$NVS $OLMA $RHHBY $XBI Will we get a buyout PR soon?
0 · Reply
green_going_up
green_going_up Apr. 1 at 3:50 AM
$CLGN Aesthetic Wellness is one of the fastest growing markets; this firm has a development deal with $ABBV yet can't get any interest; reminds me of $LCTX which has a development deal with $RHHBY for GA; these firms get tiny milestone payments and just sit there waiting, hoping, and praying for these big firms to fully commit. They can take YEARS. And, you wonder if firm's like Abbvie and Roche don't just play the long game on purpose, eventually being able to pick up these micro-cap firm assets on the cheap once either these firms file for bankruptcy or dilute themselves so much because the shorts / naked shorts just pound them relentless until they are forced to de-list. Firms like these micro-cap ones MUST have really strong CFO's to raise way more than what's needed - Years Worth of Cash - in the period right after the initial partnership announcement spike. Otherwise, surviving the waiting game is a serious challenge.
2 · Reply
patatechaude
patatechaude Mar. 31 at 7:19 PM
Come on $NVS, make your offer… get $OLMA and beat $RHHBY to it. $3B should do. $XBI
0 · Reply
Lowkeyoptions
Lowkeyoptions Mar. 30 at 8:42 PM
$BFRG Based on 2024–2025 revenue data, the top pharmaceutical companies are dominated by Pfizer, Merck & Co., Johnson & Johnson, AbbVie, and Roche. These companies lead in manufacturing vaccines, oncology drugs, and innovative therapies, with several, particularly Pfizer, rebounding from lower COVID-19 product demand. Top 5 Pharmaceutical Companies (by 2024/2025 Revenue): $PFE Often leads by revenue due to COVID-19 vaccines and vaccines like Prevnar, though facing pressure to diversify. $MERCK (USA): Known for cancer immunotherapy Keytruda, which has driven significant growth, placing them high in the rankings. $JNJ Johnson & Johnson (USA): A diversified healthcare leader with strong positions in pharmaceuticals and medical $ABBV (USA): Known for immunology treatments like Humira, maintaining a top spot despite patent challenges. $RHHBY Roche (Switzerland): A leader in oncology and diagnostics, often ranking top five due to its specialized, high-cost therapies.
0 · Reply
scotttrader213
scotttrader213 Mar. 30 at 7:54 PM
$RHHBY holding steady
0 · Reply
Tom2772
Tom2772 Mar. 30 at 12:30 PM
$QBTS $PFIZER.NSE $NVS $RHHBY Focus: faster chemical discovery & optimization using AI + quantum computing drug discovery → powered by D-Wave Quantum Inc. synthesis optimization → powered by D-Wave Quantum Inc. reaction pathway optimization → core strength of D-Wave Quantum Inc. combinatorial chemistry problems → core strength of D-Wave Quantum Inc. AI-guided molecule design → supported by D-Wave Quantum Inc. hybrid quantum-classical workflows → enabled by D-Wave Quantum Inc. Quantum = Faster!
0 · Reply
Tom2772
Tom2772 Mar. 30 at 11:45 AM
$QBTS $PFIZER.NSE $NVS $RHHBY Through this research project, Redwood will work closely with QAI and UBC to integrate quantum computing techniques into AI-driven chemical synthesis workflows. As part of the project, Redwood will gain access to advanced quantum infrastructure, including hardware platforms developed by D-Wave Quantum Inc. By combining artificial intelligence with quantum computing methods, the project aims to support faster and more efficient approaches to chemical synthesis, with the potential to one day reduce research timelines and costs for applications such as pharmaceutical development and defense applications. Redwood AI, Quantum Algorithms Institute and UBC to Launch Mitacs Accelerate Project for Accelerating Chemical Synthesis with AI and Quantum Computing – Redwood AI https://share.google/SWTwY4eIzIMrobF0z Quantum = Faster !
0 · Reply
Biotech_Beast
Biotech_Beast Mar. 28 at 2:58 AM
$AUPH New leader, new officers, reduced compensation, Lupkynis still growing, and yet the name has pulled back from highs. I'm back to a buy rating on AUPH. $RHHBY Gazyva launch so far hasn't dented the momentum of Lupkynis, although we'll have to see a few more quarters of data I think. https://seekingalpha.com/article/4886701-aurinia-pharmaceuticals-new-management-continued-lupkynis-performance
2 · Reply
StockWookie
StockWookie Mar. 27 at 7:00 PM
$SRPT One day you will wake up with 2 share of Roche $RHHBY for 1 shares of Serpeta !
2 · Reply
BlackSwan13
BlackSwan13 Mar. 27 at 3:50 PM
$RHHBY If they can manage their supply chain we will be good.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Mar. 27 at 3:26 PM
$SLS the Market Cap, Market Value of SLS is up 1,600% in the last year since the IDMC Unblinded Actual Phase 3 Median Overall Survival and Immune Response Data - that told, everyone paying attention, GPS is 100% for Sure Getting Fda Approval - GUARANTEED. $ABBV $RHHBY and $BMY who own Aza and VEN - Know Precisely how their drugs work for AML Remission patients, they know GPS is the only reason we are and have been seeing Miraculous All Pooled Survival Data.
0 · Reply
Hellozz
Hellozz Mar. 26 at 3:28 PM
$SRPT lol filtering out paper hands.. posssible BO offer from $RHHBY . This is the last time $RHHBY can have this gem below $100
0 · Reply
Quantumup
Quantumup Mar. 26 at 11:32 AM
Stifel⬆️ $CELC's PT to $125 from $115 and reiterated a Buy rating. $RLAY $RHHBY LLY BBOT NVS BGNE Here's what Stifel said in its note: https://x.com/Quantumup1/status/2037129947924336805?s=20
0 · Reply
IndyOne
IndyOne Mar. 24 at 1:55 PM
$MRNA Follow the bread crumbs: October 2025: STET rumored Moderna "deal of significant scope" in discussion, buyout or massive partnership. December 2025: Stéphane Bancel, Moderna CEO, sold his six-level home in Boston where he has lived for +12 years. January 2026: Moderna and Merck announced five-year follow-up data from the Phase 2b KEYNOTE-942 trial showed a 49% reduction in the risk of recurrence or death. Keytruda goes off patent soon, Merck can use Moderna's mRNA-4157 (also known as V940 or intismeran autogene) a first-of-its-kind, personalized mRNA cancer vaccine to extend Keytruda protection. February 2026: Patent litigation resolved with payment from Moderna. Moderna wanted the decks clear, they could have fought this longer like Pfizer & Biontech. NO ROYALTIES! HUGE WIN. Likely buyout coming from $MRK $PFE $JNJ or $RHHBY
1 · Reply
Quantumup
Quantumup Mar. 23 at 11:52 AM
H.C. Wainwright⬆️ $RLAY's PT to $19 and reiterated at a Buy rating. $RHHBY NVS PFE LLY AZN $CELC H.C. Wainwright said—Relay recently reported data from the Phase 1/2 ReDiscover trial of zovegalisib (RLY-2608) + Faslodex (fulvestrant) at the recommended Phase 3 dose of 400mg twice-daily (BID) taken with food in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer. As seen in the presentation, zovegalisib 400mg BID + Faslodex (n=60; 1 median prior Rx) demonstrated a 42.9% ORR (52.4% ORR in 2L patients), with a mPFS of 11.1 months. After pulling our discounted cash flow (DCF)-based valuation forward and taking into account lower long-term operating expenses, we reiterate our Buy rating, while raising our 12-month price target to $19 from the prior $14 per share.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Mar. 20 at 3:50 PM
$SLS @Bcon852 Phase 3 Results / 80th event Could occur at Any Time - it is conceivable, and offers a Slight discount - so possible. -- Pharma's have enough, know enough, Aza+VEN Failed 3 Large Phase 3 Trials, including 2 for AML Remission Maintenance - VIALE-M and VIALE-T both Failed. $ABBV $BMY $RHHBY who conducted the trials, Know Precisely how their Drugs work or don't work for AML Patients IN REMISSION/ they also see the Extended GPS P3 Data, like everyone Else - 54 of 128 Survivors at 2 YEARS - is a miracle for these AML CR2 Transplant Ineligible Patients. - So they May be Willing to Pay Something Reasonably CLose to Angelos 'Max Value' Requirement. -We know SLS is for Sale - we Know there has been buyer interest, we know there are ongoing negotiations and the Last words on the subject from the CEO were " we will let the public know when we have something concrete ". -8k Change of Control GC/CFO options accelerating. - no RSU's - no hiring of commercial team ... and more
0 · Reply
DonCorleone77
DonCorleone77 Mar. 19 at 6:54 PM
$SRRK $RHHBY Cantor sees Scholar Rock dominating SMA market after Genentech news Cantor Fitzgerald analyst Eric Schmidt says Roche's (RHHBY) Genentech sent a letter today to the spinal muscular atrophy community that included an update on the development of emugrobart, an anti-myostatin antibody. According to the letter, Genentech made the decision not to advance emugrobart. Cantor says emugrobart was trailing Scholar Rock's (SRRK) apitegromab in development by several years, and "offered little in the way of differentiation." The firm now expects apitegromab to have "near complete market share" as the lone muscle-building therapy for SMA patients. It continues to view apitegromab's FDA approval as a likely 2026 event. The firm sees multi-billion dollar potential for the drug and notes Scholar Rock continues to be a top pick.
1 · Reply